Ayse Filiz Kosar
Research Subjects
Research Interests
Ayse Filiz Kosar has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Burcu Arpinar Yigitbas
Istanbul Medeniyet University Faculty of Medicine, Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Department of Pulmonology, Istanbul, Türkiye
2 shared publications - Sibel Yurt
Basaksehir Cam and Sakura City Hospital, Department of Pulmonology, Istanbul, Turkey
2 shared publications Akbaş Turkay
Department of Internal Medicine, Section of Intensive Care, School of Medicine, Duzce University, Istanbul, Turkey
1 shared publication- Aysegul Erinc
Department of Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Health Sciences University, 34020 Istanbul, Turkey
1 shared publication Barış ŞEKER
1 shared publicationBasak Hacibedel
C Pfizer Pharmaceuticals , Health Economics and Outcomes Research , Istanbul , Turkey
1 shared publication
Latest Publications
- 1 December 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 294, 103771
Area under flow-volume loop may predict severe exacerbation in COPD patients with high grade of dyspnea
- 1 December 2021
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 294, 103771
Area under flow-volume loop may predict severe exacerbation in COPD patients with high grade of dyspnea
- Open Access
- 10 March 2017
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (7) , 1673-1680
Burden of community-acquired pneumonia in adults over 18 y of age
This study aimed to determine the economic burden and affecting factors in adult community-acquired pneumonia (CAP) patients (≥ 18 years) by retrospectively evaluating the data of 2 centers in Istanbul province, Turkey. Data of outpatients and inpatients with CAP from January 2013 through June 2014 were evaluated. The numbers of laboratory analyses, imaging, hospitalization days, and specialist visits were multiplied by the relevant unit costs and the costs of the relevant items per patient were obtained. Total medication costs were calculated according to the duration of use and dosage. The mean age was 61.56 ± 17.87 y for the inpatients (n = 211; 48.6% female) and 53.78 ± 17.46 y for the outpatients (n = 208; 46.4% male). The total mean cost was €556.09 ± 1,004.77 for the inpatients and €51.16 ± 40.92 for the outpatients. In the inpatients, laboratory, medication, and hospitalization costs and total cost were significantly higher in those ≥ 65 y than in those <65 y. Besides the hospitalization duration, specialist visit, imaging, laboratory, medication, and hospitalization costs and total cost were significantly higher in those hospitalized more than once than in those hospitalized once. While the specialist visit cost was higher in the inpatients with comorbidities, the imaging cost was higher in the outpatients with comorbidities. CAP poses a higher cost in inpatients, elders, and individuals with comorbidities. Costs can be decreased by rational decisions about hospitalization and antibiotic use according to the recommendations of guidelines and authorities. Vaccination may decrease medical burden and contribute to economy by preventing the disease, especially in risk groups.
- 10 March 2017
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (7) , 1673-1680
Open AccessBurden of community-acquired pneumonia in adults over 18 y of age
This study aimed to determine the economic burden and affecting factors in adult community-acquired pneumonia (CAP) patients (≥ 18 years) by retrospectively evaluating the data of 2 centers in Istanbul province, Turkey. Data of outpatients and inpatients with CAP from January 2013 through June 2014 were evaluated. The numbers of laboratory analyses, imaging, hospitalization days, and specialist visits were multiplied by the relevant unit costs and the costs of the relevant items per patient were obtained. Total medication costs were calculated according to the duration of use and dosage. The mean age was 61.56 ± 17.87 y for the inpatients (n = 211; 48.6% female) and 53.78 ± 17.46 y for the outpatients (n = 208; 46.4% male). The total mean cost was €556.09 ± 1,004.77 for the inpatients and €51.16 ± 40.92 for the outpatients. In the inpatients, laboratory, medication, and hospitalization costs and total cost were significantly higher in those ≥ 65 y than in those <65 y. Besides the hospitalization duration, specialist visit, imaging, laboratory, medication, and hospitalization costs and total cost were significantly higher in those hospitalized more than once than in those hospitalized once. While the specialist visit cost was higher in the inpatients with comorbidities, the imaging cost was higher in the outpatients with comorbidities. CAP poses a higher cost in inpatients, elders, and individuals with comorbidities. Costs can be decreased by rational decisions about hospitalization and antibiotic use according to the recommendations of guidelines and authorities. Vaccination may decrease medical burden and contribute to economy by preventing the disease, especially in risk groups.
- Open Access
- 1 January 2016
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 79 (3) , 158-164
Characteristics of Active Tuberculosis Patients Requiring Intensive Care Monitoring and Factors Affecting Mortality
Filiz KA, et al. Tuberc Respir Dis. 2016 Jul;79(3):158-164. http://dx.doi.org/10.4046/trd.2016.79.3.158
- 1 January 2016
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 79 (3) , 158-164
Open AccessCharacteristics of Active Tuberculosis Patients Requiring Intensive Care Monitoring and Factors Affecting Mortality
Filiz KA, et al. Tuberc Respir Dis. 2016 Jul;79(3):158-164. http://dx.doi.org/10.4046/trd.2016.79.3.158
- 29 December 2015
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 63 (4) , 243-249
The comparative value of pleural fluid adenosine deaminase and neopterin levels in diagnostic utility of pleural tuberculosis
The aim of the present study was to evaluate and compare the diagnostic accuracy of pleura levels of adenosine deaminase (ADA) and neopterin for the differential diagnosis of pleural tuberculosis (TP). The study included 50 patients with TB, 27 patients with malignancies, and 24 patients with pleural effusion of non-tuberculous and non-malignant origin as controls. ADA and neopterin levels in pleural fluid were measured by spectrofotometric and ELISA method, respectively. Pleural neopterin levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001). Pleural ADA levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001) and patients with benign non-tuberculosis effusions (p< 0.001). The mean levels of ADA and neopterin in pleural effusion were evaluated according to their underlying diseases for the diagnostic accuracy. As for pleural TB receiving operating characteristic curves identified the following results; The best cut-off value for pleural neopterin was 4.7 U/L and yielded a sensitivity and specificity of 86% and 72.55%, respectively. Taking a cut-off value of 42 U/L for pleural ADA, the sensitivity and the specificity were found to be 88% and 68.63%, respectively. In the diagnosis of pleural TB pleural neopterin level has a comparable sensitivity to pleural ADA activity. Both markers may find a place as a routine investigation in the coming days for early detection of TB. However, these tests should not be considered an alternative to biopsy and culture.
- 29 December 2015
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 63 (4) , 243-249
The comparative value of pleural fluid adenosine deaminase and neopterin levels in diagnostic utility of pleural tuberculosis
The aim of the present study was to evaluate and compare the diagnostic accuracy of pleura levels of adenosine deaminase (ADA) and neopterin for the differential diagnosis of pleural tuberculosis (TP). The study included 50 patients with TB, 27 patients with malignancies, and 24 patients with pleural effusion of non-tuberculous and non-malignant origin as controls. ADA and neopterin levels in pleural fluid were measured by spectrofotometric and ELISA method, respectively. Pleural neopterin levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001). Pleural ADA levels were significantly higher in patients with pleural TB than patients with malignancy (p< 0.001) and patients with benign non-tuberculosis effusions (p< 0.001). The mean levels of ADA and neopterin in pleural effusion were evaluated according to their underlying diseases for the diagnostic accuracy. As for pleural TB receiving operating characteristic curves identified the following results; The best cut-off value for pleural neopterin was 4.7 U/L and yielded a sensitivity and specificity of 86% and 72.55%, respectively. Taking a cut-off value of 42 U/L for pleural ADA, the sensitivity and the specificity were found to be 88% and 68.63%, respectively. In the diagnosis of pleural TB pleural neopterin level has a comparable sensitivity to pleural ADA activity. Both markers may find a place as a routine investigation in the coming days for early detection of TB. However, these tests should not be considered an alternative to biopsy and culture.
- Open Access
- 6 March 2014
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 9 (1) , 12
Diagnostic utility of serum and pleural levels of adenosine deaminase 1–2, and interferon-γ in the diagnosis of pleural tuberculosis
To evaluate and compare the diagnostic efficiency of serum (s) and pleural (p) levels of adenosine deaminase (ADA)-1, ADA-2, total ADA, and interferon-gamma (IFN-γ) for the differential diagnosis of pleural tuberculosis (TB).
- 6 March 2014
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 9 (1) , 12
Open AccessDiagnostic utility of serum and pleural levels of adenosine deaminase 1–2, and interferon-γ in the diagnosis of pleural tuberculosis
To evaluate and compare the diagnostic efficiency of serum (s) and pleural (p) levels of adenosine deaminase (ADA)-1, ADA-2, total ADA, and interferon-gamma (IFN-γ) for the differential diagnosis of pleural tuberculosis (TB).